This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bickert, B. Articles by Reilly, A. Search for Related Content Social Bookmarking                         What's this?

Pediatric Tumor Lysis Syndrome

Department of Pharmacy Services, Children’s Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104bickert{at}email.chop.edu

Anne Reilly, MD, MPH

Division of Oncology, Children’s Hospital of Philadelphia, 34th and Civic Center Boulevard, Philadelphia, PA 19104

Patients with a high tumor burden may develop tumor lysis syndrome. Tumor lysis syndrome consists of at least 2 metabolic abnormalities, which may include hyperkalemia, hyperphosphatemia, or hyperuricemia. The goal of standard therapy is to prevent tumor lysis syndrome. Prophylactic therapy includes hydration, alkalinization, and treatment to lower uric acid with either allopurinol or rasburicase. Other metabolic abnormalities are treated as they occur.

Key Words: Tumor lysis syndrome • allopurinol • rasburicase • children

Journal of Pharmacy Practice, Vol. 17, No. 6, 447-454 (2004)
DOI: 10.1177/0897190004272552


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?